Additional Study Information: The purpose of this study is to test the safety and dose of CDK-002 alone in subjects with cancer that is considered advanced and/or has spread to other parts of the body. CDK-002 is an investigational study drug that is being developed for the potential treatment of cancer. This is a first-in-human study. CDK-002 is a drug designed to activate the immune system so that it tries to kill cancer cells. CDK-002 will be injected directly into cancer tumors. This may be done using a CT scan or an ultrasound to help guide the injection. Cancers include breast cancer, head and neck/oral cancers, skin cancers, melanoma, and thyroid cancer.